RIPK1 and metabolic dysfunction-associated steatohepatitis: These results indicate that treatment of UDP-GlcA has the ability to prevent NASH-associated liver damage and fibrosis by suppressing RIPK1 activation and hepatocyte apoptosis, and thus UDP-GlcA may represent a promising agent for the therapy of theses pathological conditions.